Cargando…

Evaluating HIV Viral Rebound Among Persons on Suppressive Antiretroviral Treatment in the Era of “Undetectable Equals Untransmittable (U = U)”

BACKGROUND: Studies have demonstrated that persons with HIV (PWH) maintaining viral suppression do not transmit HIV to HIV-negative partners through condomless sex, leading to the “Undetectable = Untransmittable (U = U)” prevention campaign. However, few studies have examined the durability of suppr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Sugi, Gillani, Fizza S, Aung, Su, Garland, Joseph M, Beckwith, Curt G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731526/ https://www.ncbi.nlm.nih.gov/pubmed/33335935 http://dx.doi.org/10.1093/ofid/ofaa529

Ejemplares similares

From Undetectable Equals Untransmittable (U=U) to Breastfeeding: Is the Jump Short?
por: Prestileo, Tullio, et al.
Publicado: (2022)

994. Risk for Viral Rebound in the Era of U=U; A CNICS Analysis
por: Hansen, Blake, et al.
Publicado: (2020)

Challenges to communicating the Undetectable equals Untransmittable (U=U) HIV prevention message: Healthcare provider perspectives
por: Grace, Daniel, et al.
Publicado: (2022)

A call to improve understanding of Undetectable equals Untransmittable (U = U) in Brazil: a web‐based survey
por: Torres, Thiago S, et al.
Publicado: (2020)

Risk of HIV Viral Rebound in the Era of Universal Treatment in a Multicenter Sample of Persons With HIV in Primary Care
por: Liu, Tao, et al.
Publicado: (2023)

Undetectable equals untransmittable (U = U): awareness and associations with health outcomes among people living with HIV in 25 countries
por: Okoli, Chinyere, et al.
Publicado: (2021)

HIV-Related Stigma Reduction in the Era of Undetectable Equals Untransmittable: The South Korean Perspective
por: Choi, Jae-Phil, et al.
Publicado: (2021)

Understanding the Risk of Human Immunodeficiency Virus (HIV) Virologic Failure in the Era of Undetectable Equals Untransmittable
por: Gunn, Jayleen K. L., et al.
Publicado: (2021)

Promoting Undetectable Equals Untransmittable in Sub-Saharan Africa: Implication for Clinical Practice and ART Adherence
por: Thomford, Nicholas Ekow, et al.
Publicado: (2020)

Undetectable = Untransmittable (U = U) Messaging Increases Uptake of HIV Testing Among Men: Results from a Pilot Cluster Randomized Trial
por: Smith, Philip, et al.
Publicado: (2021)

76. Effects of the “Undetectable = Untransmittable” (“U=U”) Educational Campaign on Treatment Outcomes and Perceptions among People Living with HIV in North American Countries
por: Spinelli, Frank, et al.
Publicado: (2021)

HIV knowledge and its correlation with the Undetectable = Untransmittable slogan in Brazil
por: Ferreira, Rayane C., et al.
Publicado: (2022)

Changing Knowledge and Attitudes Towards HIV Treatment-as-Prevention and “Undetectable = Untransmittable”: A Systematic Review
por: Bor, Jacob, et al.
Publicado: (2021)

LGBTQ+ AFFIRMING CARE AND UNDETECTABLE=UNTRANSMITTABLE: EVIDENCE FOR OLDER GAY AND BISEXUAL MEN IN THE US SOUTH
por: Akre (she/her), Ellesse-Roselee, et al.
Publicado: (2022)

Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression
por: Castillo-Mancilla, Jose R, et al.
Publicado: (2023)

Early Initiation of Antiretroviral Therapy Following In Utero HIV Infection Is Associated With Low Viral Reservoirs but Other Factors Determine Viral Rebound
por: Millar, Jane R, et al.
Publicado: (2021)

Awareness, Understanding and HIV Stigma in Response to Undetectable = Untransmittable Messages: Findings from a Nationally Representative Sample in the United Kingdom
por: Coyne, Rory, et al.
Publicado: (2022)

“I just believe there is a risk” understanding of undetectable equals untransmissible (U = U) among health providers and HIV‐negative partners in serodiscordant relationships in Kenya
por: Ngure, Kenneth, et al.
Publicado: (2020)

LGBTQ+ Affirming Care May Increase Awareness and Understanding of Undetectable = Untransmittable among Midlife and Older Gay and Bisexual Men in the US South
por: McKay, Tara, et al.
Publicado: (2022)

Factors associated with perceived accuracy of the Undetectable = Untransmittable slogan among men who have sex with men: Implications for messaging scale‐up and implementation
por: Rendina, H Jonathon, et al.
Publicado: (2018)

1944. Patients With Prosthetic Joint Infections Receiving Outpatient Parenteral Antimicrobial Therapy: Characteristics and Readmission Rates
por: Gore, Sara, et al.
Publicado: (2018)

A New Era in Understanding Diabetes Disparities Among U.S. Latinos—All Are Not Equal
por: López, Lenny, et al.
Publicado: (2014)

Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status
por: Gowda, Charitha, et al.
Publicado: (2017)

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy
por: Huntington, Susie, et al.
Publicado: (2015)

Infectious disease surveillance in U.S. jails: Findings from a national survey
por: Maner, Morgan, et al.
Publicado: (2022)

Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era
por: Wood, Shannon, et al.
Publicado: (2021)

Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination: A case report with implications for clinical care
por: Koofhethile, Catherine Kegakilwe, et al.
Publicado: (2019)

518. Factors Associated with Severe COVID-19 among Patients Hospitalized in Rhode Island
por: Pandita, Aakriti, et al.
Publicado: (2020)

The strength of rebound: patient care and financial consequences of COVID-19 in U.S. pediatric ophthalmology
por: Robbins, Shira L., et al.
Publicado: (2021)

Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience
por: Kalligeros, Markos, et al.
Publicado: (2020)

Gender differences for frailty in HIV-infected patients on stable antiretroviral therapy and with an undetectable viral load
por: Blanco, José-Ramón, et al.
Publicado: (2019)

Factors Associated With Cancer Incidence and With All-Cause Mortality After Cancer Diagnosis Among Human Immunodeficiency Virus-Infected Persons During the Combination Antiretroviral Therapy Era
por: Patel, Pragna, et al.
Publicado: (2014)

“To Be Honest, You Probably Would Have to Read It 50 Times”: Stakeholders Views on Using the Opt-Out Approach for Vaccination in Jails
por: Lodolo, Laura, et al.
Publicado: (2023)

Vaccine breakthrough and rebound infections modeling: Analysis for the United States and the ten U.S. HHS regions
por: Otunuga, Olusegun Michael, et al.
Publicado: (2023)

Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA
por: Novitsky, Vlad, et al.
Publicado: (2021)

Cryptococcal Antigen Screening Among Antiretroviral Therapy–Experienced People With HIV With Viral Load Nonsuppression in Rural Uganda
por: Baluku, Joseph Baruch, et al.
Publicado: (2021)

Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy
por: Bernal, Silvia, et al.
Publicado: (2023)

Am I Positive? Improving Human Immunodeficiency Virus Testing in the Era of Preexposure Prophylaxis and Immediate Antiretroviral Therapy Using Machine Learning
por: Zucker, Jason, et al.
Publicado: (2022)

Defective Monocyte Enzymatic Function and an Inhibitory Immune Phenotype in Human Immunodeficiency Virus-Exposed Uninfected African Infants in the Era of Antiretroviral Therapy( )
por: Afran, Louise, et al.
Publicado: (2022)

Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island
por: Pandita, Aakriti, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mt4c0lamdfc516090t1opnouu8